Ross Moat - Apr 21, 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Apr 21, 2025
Transactions value $
-$370,475
Form type
4
Date filed
4/23/2025, 04:44 PM
Previous filing
Apr 9, 2025
Next filing
May 1, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Sale -$370K -18.3K -65.98% $20.29 9.42K Apr 21, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.
F2 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $20.05 and 20.53. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.